Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	May 14, 2014	P	14,500	$9.4555	A	2,029,083	I	See Footnotes
Common Stock^F1,F2,F3	May 14, 2014	P	2,200	$9.4555	A	2,031,283	I	See Footnotes
Common Stock^F1,F2,F3	May 15, 2014	P	94,021	$9.2296	A	2,125,304	I	See Footnotes
Common Stock^F1,F2,F3	May 15, 2014	P	67,800	$9.2296	A	2,193,104	I	See Footnotes
Common Stock^F1,F2,F3	May 15, 2014	P	10,400	$9.2296	A	2,203,504	I	See Footnotes
Common Stock^F1,F2,F3	May 15, 2014	P	1,500	$9.2296	A	2,205,004	I	See Footnotes
Common Stock^F1,F2,F3	May 16, 2014	P	27,988	$9.2532	A	2,232,992	I	See Footnotes
Common Stock^F1,F2,F3	May 16, 2014	P	20,300	$9.2532	A	2,253,292	I	See Footnotes
Common Stock^F1,F2,F3	May 16, 2014	P	3,200	$9.2532	A	2,256,492	I	See Footnotes
Common Stock^F1,F2,F3	May 16, 2014	P	300	$9.2532	A	2,256,792	I	See Footnotes
Common Stock^F1,F2,F3	Jun 6, 2014	P	1,386,600	$9.50	A	3,643,392	I	See Footnotes
Common Stock^F1,F2,F3	Jun 6, 2014	P	946,700	$9.50	A	4,590,092	I	See Footnotes
Common Stock^F1,F2,F3	Jun 6, 2014	P	144,700	$9.50	A	4,734,792	I	See Footnotes
Common Stock^F1,F2,F3	Jun 6, 2014	P	22,000	$9.50	A	4,756,792	I	See Footnotes
Common Stock^F1,F2,F3	Sep 30, 2014	P	11,300	$2.7679	A	4,768,092	I	See Footnotes
Common Stock^F1,F2,F3	Nov 1, 2016	J	41,900	$2.00	D	4,726,192	I	See Footnotes
Common Stock^F1,F2,F3	Feb 1, 2017	S	800	$2.1131	D	4,725,392	I	See Footnotes
Common Stock^F1,F2,F3	Feb 2, 2017	S	10,500	$2.1618	D	4,714,892	I	See Footnotes
Common Stock^F5,F1,F2,F3	Feb 5, 2018	J	20,000,000	—	A	24,714,892	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant^F12,F1,F2,F3	$1.91	Aug 20, 2015	P	4,000,000	A	Aug 20, 2015	Aug 20, 2023	Common Stock	4,000,000	4,000,000	I
Warrant^F1,F2,F3	$1.25	Feb 5, 2018	J	4,000,000	A	Dec 31, 2018	Dec 31, 2020	Common Stock	4,000,000	8,000,000	I

Explanation of responses

F1This Form 4 is being filed by Waddell & Reed Financial, Inc. ("WDR") on behalf of itself and Waddell & Reed Financial Services, Inc. ("WRFSI"), Waddell & Reed, Inc. ("WRI"), Waddell & Reed Investment Management Company ("WRIMCO"), and Ivy Investment Management Company ("IICO" and, together with WDR, WRFSI, WRI, and WRIMCO, the "Reporting Persons").
F10The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.08 to $2.15, inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.15 to $2.18, inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12On August 20, 2015, Marrone Bio Innovations, Inc. issued and sold to Ivy Science & Technology Fund, Waddell & Reed Advisors Science & Technology Fund and Ivy VIP Science & Technology senior secured promissory notes in the aggregate principal amount of $40,000,000 and warrants to purchase up to 4,000,000 shares of Common Stock for an aggregate consideration of $40,000,000.
F2The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts which are advised or sub-advised by IICO, an investment advisory subsidiary of WDR (a publicly traded company) or WRIMCO (an investment advisory subsidiary of WRI). WRI is a broker-dealer and underwriting subsidiary of WRFSI, and WRFSI is a subsidiary of WDR. Pursuant to investment sub-advisory contracts, IICO and WRIMCO are granted investment power and, in most cases, voting power, over securities owned by sub-advisory clients. Therefore, IICO and/or WRIMCO may be deemed the beneficial owner of the securities covered by this Form 4. Indirect "beneficial ownership," if any, of any such securities is attributed to the respective parent companies solely because of the parent companies' control relationship to WRIMCO and IICO.
F3In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the Issuer's securities that the Reporting Persons may be deemed to beneficially own is reported herein. Each of WDR, WRFSI, WRI, WRIMCO, and IICO disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F4Represents securities in a managed account that are no longer advised by IICO and/or WRIMCO following the termination of the relevant sub-advisory agreement by IICO and/or WRIMCO.
F5On February 5, 2018, Marrone Bio Innovations, Inc. converted, pursuant to an amendment, dated December 15, 2017, to the senior secured promissory notes, dated as of August 20, 2015, in the aggregate principal amount of $40,000,000 (the "Waddell Notes"), issued and sold to Ivy Science & Technology Fund, Waddell & Reed Advisors Science & Technology Fund and Ivy VIP Science & Technology, $35,000,000 aggregate principal amount of the Waddell Notes into an aggregate of 20,000,000 shares of Common Stock, a $1.75 per share conversion rate, and 4,000,000 warrants to purchase shares of Common Stock.
F6The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.262 to $9.60, inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.091 to $9.27, inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.30 , inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.65 to $2.86, inclusive. The reporting person undertakes to provide Marrone Bio Innovations, Inc., any security holder of Marrone Bio Innovations, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks

Exhibit List: Exhibit 99.1 - Joint Filer Information